SMC3 Is Highly Expressed in Gliomas and Is Associated With Favorable Prognosis and B Cell-Related Immune Features

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• The cohesin component SMC3 has roles in tumorigenesis, but its function in gliomas is unclear.
• Its expression, prognostic value, and immune microenvironment links in gliomas need further investigation.

Purpose of the Study:

• To investigate SMC3 expression, prognostic significance, and immune microenvironment associations in glioma.
• To explore potential B cell-related signaling pathways linked to SMC3.

Main Methods:

• Systematic analysis of SMC3 expression in glioma datasets (CGGA, TCGA, GEO) and clinical specimens.
• Assessment of overall survival (OS) using Kaplan-Meier and Cox regression.
• Evaluation of immune microenvironment and pathway enrichment (GSEA), focusing on B cell-related genes.

Main Results:

• SMC3 was overexpressed in gliomas, with higher levels in lower-grade gliomas (LGG) than glioblastoma (GBM).
• High SMC3 expression correlated with prolonged OS and favorable prognosis in specific subgroups.
• SMC3 expression linked to lower immune/stromal scores but increased B cell and plasma cell infiltration, and PI3K-AKT-MYC pathway activation.

Conclusions:

• SMC3 is upregulated in gliomas and serves as a favorable prognostic biomarker.
• SMC3 expression is associated with B cell infiltration and PI3K-Akt-MYC signaling in gliomas.
• SMC3 may influence glioma immune microenvironments, potentially via B cell-mediated mechanisms.